Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus AI (TEM) Reports Q1 Loss, Beats Revenue Estimates
06:16pm, Tuesday, 05'th May 2026
Tempus AI (TEM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.24 per share a year ago.
Tempus Reports First Quarter 2026 Results
04:01pm, Tuesday, 05'th May 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte
Can Nancy Pelosi’s Favorite AI Stock Hope to Regain Its Momentum?
02:56pm, Monday, 04'th May 2026
Investors are watching Tempus AI (NASDAQ: TEM) ahead of first-quarter results due after the close tomorrow. The stock burst into investor consciousness in January 2025 after Nancy Pelosi disclosed a p
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
02:50pm, Thursday, 30'th Apr 2026
TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.
TruBridge (TBRG) Earnings Expected to Grow: What to Know Ahead of Q1 Release
11:02am, Wednesday, 29'th Apr 2026
TruBridge (TBRG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus to Host Inaugural Investor Day on May 29, 2026
08:30am, Wednesday, 29'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the company will host an Investor Day on Fr
Tempus AI (TEM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:09am, Tuesday, 28'th Apr 2026
Tempus (TEM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempus Named to TIME's 10 Most Influential Health and Life Science Companies of 2026
08:30am, Tuesday, 28'th Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company advancing precision medicine through the practical application of artificial intelligence, today announced it has been nam
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
09:20am, Monday, 27'th Apr 2026
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
Tempus AI Nears Profitability as Operating Leverage Emerges
03:21pm, Friday, 24'th Apr 2026
TEM nears profitability as gross profit surges and EBITDA turns positive, but persistent GAAP losses keep focus on long-term operating leverage.
Cathie Wood Is Loading Up on These 3 Next-Gen Tech Stocks
10:49am, Thursday, 23'rd Apr 2026
CEO Eric Lefkofsky framed the trajectory plainly: “As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years,
Tempus and USC Announce Strategic Collaboration to Accelerate AI-Driven Precision Medicine
08:30am, Thursday, 23'rd Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and the Keck School of Medicine of USC and Keck Medicine of USC,
Tempus to Report First Quarter 2026 Financial Results on May 5
08:30am, Tuesday, 21'st Apr 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the first q
Tempus AI Expands Strategic Partnership Amid Oncology Boom
01:56pm, Thursday, 16'th Apr 2026
TEM expands GenoPredicta rollout and deepens oncology partnerships, leveraging AI and WGS to advance cancer diagnostics and research.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta Biosciences, a precision oncology company developin
